106 related articles for article (PubMed ID: 14602859)
1. Delayed (18)F-FDG PET for detection of paraaortic lymph node metastases in cervical cancer patients.
Ma SY; See LC; Lai CH; Chou HH; Tsai CS; Ng KK; Hsueh S; Lin WJ; Chen JT; Yen TC
J Nucl Med; 2003 Nov; 44(11):1775-83. PubMed ID: 14602859
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of FDG PET in patients with cervical cancer.
Sugawara Y; Eisbruch A; Kosuda S; Recker BE; Kison PV; Wahl RL
J Nucl Med; 1999 Jul; 40(7):1125-31. PubMed ID: 10405131
[TBL] [Abstract][Full Text] [Related]
3. Preliminary report of using FDG-PET to detect extrapelvic lesions in cervical cancer patients with enlarged pelvic lymph nodes on MRI/CT.
Tsai CS; Chang TC; Lai CH; Tsai CC; Ng KK; Hsueh S; Yen TC; Hong JH
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1506-12. PubMed ID: 15050330
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of dual-time-point 18F-FDG PET for staging in patients with lung cancer.
Uesaka D; Demura Y; Ishizaki T; Ameshima S; Miyamori I; Sasaki M; Fujibayashi Y; Okazawa H
J Nucl Med; 2008 Oct; 49(10):1606-12. PubMed ID: 18794269
[TBL] [Abstract][Full Text] [Related]
5. Prospective evaluation of 18-fluoro-2-deoxy-D-glucose positron emission tomography for the discrimination of paraaortic nodal spread in patients with locally advanced cervical carcinoma.
Perez-Medina T; Pereira A; Mucientes J; García-Espantaleón M; Jiménez JS; Calles L; Rodríguez B; Iglesias E
Int J Gynecol Cancer; 2013 Jan; 23(1):170-5. PubMed ID: 23196756
[TBL] [Abstract][Full Text] [Related]
6. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan.
Chung JK; So Y; Lee JS; Choi CW; Lim SM; Lee DS; Hong SW; Youn YK; Lee MC; Cho BY
J Nucl Med; 1999 Jun; 40(6):986-92. PubMed ID: 10452315
[TBL] [Abstract][Full Text] [Related]
7. Detection of early recurrence with 18F-FDG PET in patients with cervical cancer.
Ryu SY; Kim MH; Choi SC; Choi CW; Lee KH
J Nucl Med; 2003 Mar; 44(3):347-52. PubMed ID: 12620999
[TBL] [Abstract][Full Text] [Related]
8. Lymph node assessment with (18)F-FDG-PET and MRI in uterine cervical cancer.
Monteil J; Maubon A; Leobon S; Roux S; Marin B; Renaudie J; Genet D; Fermeaux V; Aubard Y; Tubiana-Mathieu N
Anticancer Res; 2011 Nov; 31(11):3865-71. PubMed ID: 22110211
[TBL] [Abstract][Full Text] [Related]
9. FDG PET-CT in cervical cancer: relationship between primary tumor FDG uptake and metastatic potential.
Yilmaz M; Adli M; Celen Z; Zincirkeser S; Dirier A
Nucl Med Commun; 2010 Jun; 31(6):526-31. PubMed ID: 20215979
[TBL] [Abstract][Full Text] [Related]
10. Positron emission tomography in evaluating the feasibility of curative intent in cervical cancer patients with limited distant lymph node metastases.
Chao A; Ho KC; Wang CC; Cheng HH; Lin G; Yen TC; Lai CH
Gynecol Oncol; 2008 Aug; 110(2):172-8. PubMed ID: 18499238
[TBL] [Abstract][Full Text] [Related]
11. A prospective randomized trial to study the impact of pretreatment FDG-PET for cervical cancer patients with MRI-detected positive pelvic but negative para-aortic lymphadenopathy.
Tsai CS; Lai CH; Chang TC; Yen TC; Ng KK; Hsueh S; Lee SP; Hong JH
Int J Radiat Oncol Biol Phys; 2010 Feb; 76(2):477-84. PubMed ID: 19464824
[TBL] [Abstract][Full Text] [Related]
12. Value of whole body 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent cervical cancer.
Sun SS; Chen TC; Yen RF; Shen YY; Changlai SP; Kao A
Anticancer Res; 2001; 21(4B):2957-61. PubMed ID: 11712793
[TBL] [Abstract][Full Text] [Related]
13. The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival.
Kidd EA; Siegel BA; Dehdashti F; Grigsby PW
Cancer; 2007 Oct; 110(8):1738-44. PubMed ID: 17786947
[TBL] [Abstract][Full Text] [Related]
14. 18F-FDG uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression.
Yen TC; See LC; Lai CH; Yah-Huei CW; Ng KK; Ma SY; Lin WJ; Chen JT; Chen WJ; Lai CR; Hsueh S
J Nucl Med; 2004 Jan; 45(1):22-9. PubMed ID: 14734665
[TBL] [Abstract][Full Text] [Related]
15.
Leray H; Gabiache E; Courbon F; Brenot-Rossi I; Colineaux H; Lepage B; Lambaudie E; Martinez A; Voglimacci M; Weyl A; Deslandres M; Ducassou A; Motton S; Vaysse C; Chantalat E
J Nucl Med; 2020 Oct; 61(10):1442-1447. PubMed ID: 32034109
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment retroperitoneal para-aortic lymph node staging in advanced cervical cancer: a review.
Smits RM; Zusterzeel PL; Bekkers RL
Int J Gynecol Cancer; 2014 Jul; 24(6):973-83. PubMed ID: 24978708
[TBL] [Abstract][Full Text] [Related]
17. Dual-time-point FDG-PET for evaluation of lymph node metastasis in patients with non-small-cell lung cancer.
Nishiyama Y; Yamamoto Y; Kimura N; Ishikawa S; Sasakawa Y; Ohkawa M
Ann Nucl Med; 2008 May; 22(4):245-50. PubMed ID: 18535874
[TBL] [Abstract][Full Text] [Related]
18. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
Wagner JD; Schauwecker D; Davidson D; Logan T; Coleman JJ; Hutchins G; Love C; Wenck S; Daggy J
Cancer; 2005 Aug; 104(3):570-9. PubMed ID: 15977211
[TBL] [Abstract][Full Text] [Related]
19. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
Schaefferkoetter JD; Carlson ER; Heidel RE
J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
[TBL] [Abstract][Full Text] [Related]
20. Prediction model for para-aortic lymph node metastasis in patients with locally advanced cervical cancer.
Shim SH; Kim DY; Lee SJ; Kim SN; Kang SB; Lee SW; Park JY; Suh DS; Kim JH; Kim YM; Kim YT; Nam JH
Gynecol Oncol; 2017 Jan; 144(1):40-45. PubMed ID: 27855989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
